<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3251f617-3392-be99-e063-6294a90ae691"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use Valacyclovir Tablets safely and effectively. See full prescribing information for VALACYCLOVIR TABLETS.
 <br/>
      <br/>
VALACYCLOVIR tablets, for oral use
 <br/>
Initial U.S. Approval: 1995
</title>
   <effectiveTime value="20250409"/>
   <setId root="3251a0f1-cbfd-c9d6-e063-6394a90a09a0"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
            <name>Redpharm Drug</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="828374897"/>
                        <name>Redpharm Drug</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="67296-2146" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="3251fa7a-9988-e836-e063-6294a90a050d"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250409"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="67296-2146" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Valacyclovir</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Valacyclovir</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="69367-263" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L11K75P92J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS DIBASIC CALCIUM PHOSPHATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RDH86HJV5Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K90</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIR">
                           <quantity>
                              <numerator unit="mg" value="1000"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="G447S0T1VC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VALACYCLOVIR HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="X4HES1O11F" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ACYCLOVIR</name>
                                 </activeMoiety>
                              </activeMoiety>
                              <asEquivalentSubstance>
                                 <definingSubstance>
                                    <code code="MZ1IW7Q79D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VALACYCLOVIR</name>
                                 </definingSubstance>
                              </asEquivalentSubstance>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="21" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="67296-2146-1" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20230214"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA209553" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20230214"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48333" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="blue" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="23" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">Y132</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="3251e3f8-9eb6-fa19-e063-6394a90a31d1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20230221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Valacyclovir tablets are a deoxynucleoside analogue DNA polymerase inhibitor indicated for:</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adult Patients (
  
     <linkHtml href="#S1.1">1.1</linkHtml>)
 
    </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cold Sores (Herpes Labialis)</item>
                           <item>Genital Herpes
  
     <list listType="unordered" styleCode="Disc">
                                 <item>Treatment in immunocompetent patients (initial or recurrent episode)</item>
                                 <item>Suppression in immunocompetent or HIV-1-infected patients</item>
                                 <item>Reduction of transmission</item>
                              </list>
                           </item>
                           <item>Herpes Zoster</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Pediatric Patients (
  
     <linkHtml href="#S1.2">1.2</linkHtml>)
 
    </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Cold Sores (Herpes Labialis)</item>
                           <item>Chickenpox</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use (
  
     <linkHtml href="#S1.3">1.3</linkHtml>)
 
    </content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>The efficacy and safety of valacyclovir tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="3251e3f8-9eb7-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Adult Patients</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9eb8-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cold Sores (Herpes Labialis)</content>
                              </paragraph>
                              <paragraph>Valacyclovir tablets are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9eb9-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Genital Herpes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9eba-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Initial Episode:</content>Valacyclovir tablets are indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets when initiated more than 72 hours after the onset of signs and symptoms has not been established.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ebb-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Recurrent Episodes:</content>Valacyclovir tablets are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets when initiated more than 24 hours after the onset of signs and symptoms has not been established.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ebc-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Suppressive Therapy:</content>Valacyclovir tablets are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-1-infected adults. The efficacy and safety of valacyclovir tablets for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-1-infected patients have not been established.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ebd-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Reduction of Transmission:</content>Valacyclovir tablets are indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of valacyclovir tablets for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established. The efficacy of valacyclovir tablets for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC]
 
  <content styleCode="italics">Sexually Transmitted Diseases Treatment Guidelines).</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ebe-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Herpes Zoster</content>
                              </paragraph>
                              <paragraph>Valacyclovir tablets are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults.</paragraph>
                              <paragraph>The efficacy of valacyclovir tablets when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir tablets for treatment of disseminated herpes zoster have not been established.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="3251e3f8-9ebf-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Pediatric Patients</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ec0-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cold Sores (Herpes Labialis)</content>
                              </paragraph>
                              <paragraph>Valacyclovir tablets are indicated for the treatment of cold sores (herpes labialis) in pediatric patients aged greater than or equal to 12 years. The efficacy of valacyclovir tablets initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ec1-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Chickenpox</content>
                              </paragraph>
                              <paragraph>Valacyclovir tablets are indicated for the treatment of chickenpox in immunocompetent pediatric patients aged 2 to less than 18 years. Based on efficacy data from clinical trials with oral acyclovir, treatment with valacyclovir tablets should be initiated within 24 hours after the onset of rash
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S1.3">
                     <id root="3251e3f8-9ec2-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Limitations of Use</title>
                     <text>
                        <paragraph>The efficacy and safety of valacyclovir tablets have not been established in:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Immunocompromised patients other than for the suppression of genital herpes in HIV-1-infected patients with a CD4+ cell count greater than or equal to 100 cells/mm
  
   <sup>3</sup>.
 
  </item>
                           <item>Patients aged less than 12 years with cold sores (herpes labialis).</item>
                           <item>Patients aged less than 2 years or greater than or equal to 18 years with chickenpox.</item>
                           <item>Patients aged less than 18 years with genital herpes.</item>
                           <item>Patients aged less than 18 years with herpes zoster.</item>
                           <item>Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.</item>
                        </list>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="3251e3f8-9ec3-fa19-e063-6394a90a31d1"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Valacyclovir tablets may be given without regard to meals.</item>
                     <item>Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) may be prepared extemporaneously from the 500-mg valacyclovir tablets for use in pediatric patients for whom a solid dosage form is not appropriate
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].
  
   </content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20230221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <col width="65%" align="left" valign="top"/>
                           <col width="35%" align="left" valign="top"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td colspan="2" align="center" styleCode="Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="underline">Adult Dosage</content>
                                    </content>
                                    <content styleCode="underline">(
     
        <linkHtml href="#S2.1">2.1</linkHtml>)
    
       </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Cold Sores</td>
                                 <td styleCode="Rrule">2 grams every 12 hours for 1 day</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Genital Herpes</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Initial episode</td>
                                 <td styleCode="Rrule">1 gram twice daily for 10 days</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Recurrent episodes</td>
                                 <td styleCode="Rrule">500 mg twice daily for 3 days</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">Suppressive therapy</td>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">Immunocompetent patients</td>
                                 <td styleCode="Rrule">1 gram once daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">Alternate dose in patients with less than or equal to 9 recurrences/year</td>
                                 <td styleCode="Rrule">500 mg once daily</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">HIV-1-infected patients</td>
                                 <td styleCode="Rrule">500 mg twice daily</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Reduction of transmission</td>
                                 <td styleCode="Rrule">500 mg once daily</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Herpes Zoster</td>
                                 <td styleCode="Rrule">1 gram 3 times daily for 7 days</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="center" colspan="2" styleCode="Lrule Rrule">
                                    <content styleCode="bold">
                                       <content styleCode="underline">Pediatric Dosage</content>
                                    </content>
                                    <content styleCode="underline">(
     
        <linkHtml href="#S2.2">2.2</linkHtml>)
    
       </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule">Cold Sores (aged greater than or equal to 12 years)</td>
                                 <td styleCode="Rrule">2 grams every 12 hours for 1 day</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule">Chickenpox (aged 2 to less than 18 years)</td>
                                 <td styleCode="Rrule">20 mg/kg 3 times daily for 5 days; not to exceed 1 gram 3 times daily</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) can be prepared from the Valacyclovir Tablets, USP 500 mg. (
 
    <linkHtml href="#S2.3">2.3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="3251e3f8-9ec4-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adult Dosing Recommendations</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ec5-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cold Sores (Herpes Labialis)</content>
                              </paragraph>
                              <paragraph>The recommended dosage of valacyclovir tablets for treatment of cold sores is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ec6-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Genital Herpes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ec7-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Initial Episode:</content>The recommended dosage of valacyclovir tablets for treatment of initial genital herpes is 1 gram twice daily for 10 days. Therapy was most effective when administered within 48 hours of the onset of signs and symptoms.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ec8-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Recurrent Episodes: The recommended dosage of valacyclovir tablets for treatment of recurrent genital herpes is 500 mg twice daily for 3 days. Initiate treatment at the first sign or symptom of an episode.</paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                                 <component>
                                    <section>
                                       <id root="3251e3f8-9ec9-fa19-e063-6394a90a31d1"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>Suppressive Therapy: The recommended dosage of valacyclovir tablets for chronic suppressive therapy of recurrent genital herpes is 1 gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500 mg once daily.</paragraph>
                                          <paragraph>In HIV-1-infected patients with a CD4+ cell count greater than or equal to 100 cells/mm
 
  <sup>3</sup>, the recommended dosage of valacyclovir tablets for chronic suppressive therapy of recurrent genital herpes is 500 mg twice daily.

 </paragraph>
                                       </text>
                                       <effectiveTime value="20230221"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="3251e3f8-9eca-fa19-e063-6394a90a31d1"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Reduction of Transmission:</content>The recommended dosage of valacyclovir tablets for reduction of transmission of genital herpes in patients with a history of 9 or fewer recurrences per year is 500 mg once daily for the source partner.

 </paragraph>
                                       </text>
                                       <effectiveTime value="20230221"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ecb-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Suppressive Therapy: The recommended dosage of valacyclovir tablets for chronic suppressive therapy of recurrent genital herpes is 1 gram once daily in patients with normal immune function. In patients with a history of 9 or fewer recurrences per year, an alternative dose is 500 mg once daily.</paragraph>
                                    <paragraph>In HIV-1-infected patients with a CD4+ cell count greater than or equal to 100 cells/mm
 
  <sup>3</sup>, the recommended dosage of valacyclovir tablets for chronic suppressive therapy of recurrent genital herpes is 500 mg twice daily.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ecc-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Reduction of Transmission:</content>The recommended dosage of valacyclovir tablets for reduction of transmission of genital herpes in patients with a history of 9 or fewer recurrences per year is 500 mg once daily for the source partner.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ecd-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Herpes Zoster</content>
                              </paragraph>
                              <paragraph>The recommended dosage of valacyclovir tablets for treatment of herpes zoster is 1 gram 3 times daily for 7 days. Therapy should be initiated at the earliest sign or symptom of herpes zoster and is most effective when started within 48 hours of the onset of rash.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="3251e3f8-9ece-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Pediatric Dosing Recommendations</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ecf-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cold Sores (Herpes Labialis)</content>
                              </paragraph>
                              <paragraph>The recommended dosage of valacyclovir tablets for the treatment of cold sores in pediatric patients aged greater than or equal to 12 years is 2 grams twice daily for 1 day taken 12 hours apart. Therapy should be initiated at the earliest symptom of a cold sore (e.g., tingling, itching, or burning).</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ed0-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Chickenpox</content>
                              </paragraph>
                              <paragraph>The recommended dosage of valacyclovir tablets for treatment of chickenpox in immunocompetent pediatric patients aged 2 to less than 18 years is 20 mg/kg administered 3 times daily for 5 days. The total dose should not exceed 1 gram 3 times daily. Therapy should be initiated at the earliest sign or symptom
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>,
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="3251e3f8-9ed1-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Extemporaneous Preparation of Oral Suspension</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ed2-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Ingredients and Preparation per USP-NF</content>
                              </paragraph>
                              <paragraph>Valacyclovir tablets 500 mg, cherry flavor, and Suspension Structured Vehicle USP-NF (SSV). Valacyclovir oral suspension (25 mg/mL or 50 mg/mL) should be prepared in lots of 100 mL.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ed3-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Instructions for Preparing Suspension at Time of Dispensing</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Prepare SSV according to the USP-NF.</item>
                                 <item>Using a pestle and mortar, grind the required number of valacyclovir tablets 500-mg until a fine powder is produced (5 valacyclovir tablets for 25-mg/mL suspension; 10 valacyclovir tablets for 50-mg/mL suspension).</item>
                                 <item>Gradually add approximately 5-mL aliquots of SSV to the mortar and triturate the powder until a paste has been produced. Ensure that the powder has been adequately wetted.</item>
                                 <item>Continue to add approximately 5-mL aliquots of SSV to the mortar, mixing thoroughly between additions, until a concentrated suspension is produced, to a minimum total quantity of 20 mL SSV and a maximum total quantity of 40 mL SSV for both the 25-mg/mL and 50-mg/mL suspensions.</item>
                                 <item>Transfer the mixture to a suitable 100-mL measuring flask.</item>
                                 <item>Transfer the cherry flavor
  
   <footnote ID="K1345">The amount of cherry flavor added is as instructed by the suppliers of the cherry flavor.</footnote>to the mortar and dissolve in approximately 5 mL of SSV. Once dissolved, add to the measuring flask.
 
  </item>
                                 <item>Rinse the mortar at least 3 times with approximately 5-mL aliquots of SSV, transferring the rinsing to the measuring flask between additions.</item>
                                 <item>Make the suspension to volume (100 mL) with SSV and shake thoroughly to mix.</item>
                                 <item>Transfer the suspension to an amber glass medicine bottle with a child-resistant closure.</item>
                                 <item>The prepared suspension should be labeled with the following information "Shake well before using. 
   <br/>  Store suspension between 2° to 8°C (36° to 46°F) in a refrigerator. Discard after 28 days."
  </item>
                              </list>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="3251e3f8-9ed4-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Patients with Renal Impairment</title>
                     <text>
                        <paragraph>Dosage recommendations for adult patients with reduced renal function are provided in Table 1
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>Data are not available for the use of valacyclovir tablets in pediatric patients with a creatinine clearance less than 50 mL/min/1.73 m
 
  <sup>2</sup>.

 </paragraph>
                        <table width="80%">
                           <caption>Table 1. Valacyclovir Tablets Dosage Recommendations for Adults with Renal Impairment</caption>
                           <col width="20%" align="left" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <col width="20%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th align="center" rowspan="2" styleCode="Lrule Rrule" valign="middle">Indications</th>
                                 <th rowspan="2" styleCode="Rrule">Normal Dosage Regimen 
     <br/>  (Creatinine Clearance ≥50 mL/min)
    </th>
                                 <th colspan="3" styleCode="Rrule Botrule">Creatinine Clearance (mL/min)</th>
                              </tr>
                              <tr>
                                 <th align="center" styleCode="Lrule Rrule">30-49</th>
                                 <th styleCode="Rrule">10-29</th>
                                 <th styleCode="Rrule">&lt;10</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Cold sores (Herpes labialis ) 
      <br/>  Do not exceed 1 day of treatment.
     </content>
                                 </td>
                                 <td styleCode="Rrule">Two 2-gram doses taken 12 hours apart</td>
                                 <td styleCode="Rrule">Two 1-gram doses taken 12 hours apart</td>
                                 <td styleCode="Rrule">Two 500-mg doses taken 12 hours apart</td>
                                 <td styleCode="Rrule">500-mg single dose</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Genital herpes : 
      <br/>  Initial episode
     </content>
                                 </td>
                                 <td styleCode="Rrule">1 gram every 12 hours</td>
                                 <td styleCode="Rrule">no reduction</td>
                                 <td styleCode="Rrule">1 gram every 24 hours</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Genital herpes : 
      <br/>  Recurrent episode
     </content>
                                 </td>
                                 <td styleCode="Rrule">500 mg every 12 hours</td>
                                 <td styleCode="Rrule">no reduction</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Genital herpes: 
      <br/>  Suppressive therapy
     </content>
                                 </td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Immunocompetent patients</td>
                                 <td styleCode="Rrule">1 gram every 24 hours</td>
                                 <td styleCode="Rrule">no reduction</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Alternate dose for immunocompetent patients with less than or equal to 9 recurrences/year</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                                 <td styleCode="Rrule">no reduction</td>
                                 <td styleCode="Rrule">500 mg every 48 hours</td>
                                 <td styleCode="Rrule">500 mg every 48 hours</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">HIV-1-infected patients</td>
                                 <td styleCode="Rrule">500 mg every 12 hours</td>
                                 <td styleCode="Rrule">no reduction</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Herpes zoster</content>
                                 </td>
                                 <td styleCode="Rrule">1 gram every 8 hours</td>
                                 <td styleCode="Rrule">1 gram every 12 hours</td>
                                 <td styleCode="Rrule">1 gram every 24 hours</td>
                                 <td styleCode="Rrule">500 mg every 24 hours</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ed5-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hemodialysis</content>
                              </paragraph>
                              <paragraph>Patients requiring hemodialysis should receive the recommended dose of valacyclovir tablets after hemodialysis. During hemodialysis, the half-life of acyclovir after administration of valacyclovir tablets is approximately 4 hours. About one-third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ed6-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Peritoneal Dialysis</content>
                              </paragraph>
                              <paragraph>There is no information specific to administration of valacyclovir tablets in patients receiving peritoneal dialysis. The effect of chronic ambulatory peritoneal dialysis (CAPD) and continuous arteriovenous hemofiltration/dialysis (CAVHD) on acyclovir pharmacokinetics has been studied. The removal of acyclovir after CAPD and CAVHD is less pronounced than with hemodialysis, and the pharmacokinetic parameters closely resemble those observed in patients with end-stage renal disease (ESRD) not receiving hemodialysis. Therefore, supplemental doses of valacyclovir tablets should not be required following CAPD or CAVHD.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="3251e3f8-9ed7-fa19-e063-6394a90a31d1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Valacyclovir Tablets, USP 500-mg: Blue, film-coated, capsule-shaped tablets, debossed with "Y131" on one side contains 556.2 mg of valacyclovir hydrochloride equivalent to 500 mg of the free base.</item>
                     <item>Valacyclovir Tablets, USP 1-gram: Blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides, debossed with "Y132" on one side contains 1.112 grams of valacyclovir hydrochloride equivalent to 1 gram of the free base.</item>
                  </list>
               </text>
               <effectiveTime value="20230221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 500 mg (unscored), 1 gram (partially scored) (
 
    <linkHtml href="#S3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="3251e3f8-9ed8-fa19-e063-6394a90a31d1"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Valacyclovir tablets are contraindicated in patients who have had a demonstrated clinically significant hypersensitivity reaction (e.g., anaphylaxis) to valacyclovir, acyclovir, or any component of the formulation
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to valacyclovir (e.g., anaphylaxis), acyclovir, or any component of the formulation. (
 
    <linkHtml href="#S4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="3251e3f8-9ed9-fa19-e063-6394a90a31d1"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20230221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS): Has occurred in patients with advanced HIV-1 disease and in allogenic bone marrow transplant and renal transplant patients receiving 8 grams per day of valacyclovir tablets in clinical trials. Discontinue treatment if clinical symptoms and laboratory findings consistent with TTP/HUS occur. (
  
     <linkHtml href="#S5.1">5.1</linkHtml>)
 
    </item>
                           <item>Acute renal failure: May occur in elderly patients (with or without reduced renal function), patients with underlying renal disease who receive higher-than-recommended doses of valacyclovir tablets for their level of renal function, patients who receive concomitant nephrotoxic drugs, or inadequately hydrated patients. Use with caution in elderly patients and reduce dosage in patients with renal impairment. (
  
     <linkHtml href="#S2.4">2.4</linkHtml>,
  
     <linkHtml href="#S5.2">5.2</linkHtml>)
 
    </item>
                           <item>Central nervous system adverse reactions (e.g., agitation, hallucinations, confusion, and encephalopathy): May occur in both adult and pediatric patients (with or without reduced renal function) and in patients with underlying renal disease who receive higher-than-recommended doses of valacyclovir tablets for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Use with caution in elderly patients and reduce dosage in patients with renal impairment. (
  
     <linkHtml href="#S2.4">2.4</linkHtml>,
  
     <linkHtml href="#S5.3">5.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="3251e3f8-9eda-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome (TTP/HUS)</title>
                     <text>
                        <paragraph>TTP/HUS, in some cases resulting in death, has occurred in patients with advanced HIV-1 disease and also in allogeneic bone marrow transplant and renal transplant recipients participating in clinical trials of valacyclovir tablets at doses of 8 grams per day. Treatment with valacyclovir tablets should be stopped immediately if clinical signs, symptoms, and laboratory abnormalities consistent with TTP/HUS occur.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="3251e3f8-9edb-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Acute Renal Failure</title>
                     <text>
                        <paragraph>Cases of acute renal failure have been reported in:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Elderly patients with or without reduced renal function. Caution should be exercised when administering valacyclovir tablets to geriatric patients, and dosage reduction is recommended for those with impaired renal function
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
   
    <linkHtml href="#S8.5">Use in Specific Populations (8.5)</linkHtml>].
  
   </content>
                           </item>
                           <item>Patients with underlying renal disease who received higher-than-recommended doses of valacyclovir tablets for their level of renal function. Dosage reduction is recommended when administering valacyclovir tablets to patients with renal impairment
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
   
    <linkHtml href="#S8.6">Use in Specific Populations (8.6)</linkHtml>].
  
   </content>
                           </item>
                           <item>Patients receiving other nephrotoxic drugs. Caution should be exercised when administering valacyclovir tablets to patients receiving potentially nephrotoxic drugs.</item>
                           <item>Patients without adequate hydration. Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. Adequate hydration should be maintained for all patients.</item>
                        </list>
                        <paragraph>In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
  
   <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="3251e3f8-9edc-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Central Nervous System Effects</title>
                     <text>
                        <paragraph>Central nervous system adverse reactions, including agitation, hallucinations, confusion, delirium, seizures, and encephalopathy, have been reported in both adult and pediatric patients with or without reduced renal function and in patients with underlying renal disease who received higher-than-recommended doses of valacyclovir tablets for their level of renal function. Elderly patients are more likely to have central nervous system adverse reactions. Valacyclovir tablets should be discontinued if central nervous system adverse reactions occur
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.3">Adverse Reactions (6.3)</linkHtml>,
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="3251e3f8-9edd-fa19-e063-6394a90a31d1"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Thrombotic Thrombocytopenic Purpura/Hemolytic Uremic Syndrome
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
  
   </content>
                     </item>
                     <item>Acute Renal Failure
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].
  
   </content>
                     </item>
                     <item>Central Nervous System Effects
  
   <content styleCode="italics">[see
   
    <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].
  
   </content>
                     </item>
                  </list>
                  <paragraph>The most common adverse reactions reported in at least 1 indication by greater than 10% of adult subjects treated with valacyclovir tablets and observed more frequently with valacyclovir tablets compared with placebo are headache, nausea, and abdominal pain. The only adverse reaction reported in greater than 10% of pediatric subjects aged less than 18 years was headache.</paragraph>
               </text>
               <effectiveTime value="20230221"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The most common adverse reactions reported in at least one indication by greater than 10% of adult subjects treated with valacyclovir tablets and more commonly than in subjects treated with placebo are headache, nausea, and abdominal pain. (
  
     <linkHtml href="#S6.1">6.1</linkHtml>)
 
    </item>
                           <item>The only adverse reaction occurring in greater than 10% of pediatric subjects less than 18 years of age was headache. (
  
     <linkHtml href="#S6.2">6.2</linkHtml>)
 
    </item>
                        </list>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Westminster Pharmaceuticals, LLC at 1-844-221-7294 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="3251e3f8-9ede-fa19-e063-6394a90a31d1"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience in Adult Subjects</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9edf-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cold Sores (Herpes Labialis)</content>
                              </paragraph>
                              <paragraph>In clinical trials for the treatment of cold sores, the adverse reactions reported by subjects receiving valacyclovir tablets 2 grams twice daily (n = 609) or placebo (n = 609) for 1 day, respectively, included headache (14%, 10%) and dizziness (2%, 1%). The frequencies of abnormal ALT (greater than 2 × ULN) were 1.8% for subjects receiving valacyclovir tablets compared with 0.8% for placebo. Other laboratory abnormalities (hemoglobin, white blood cells, alkaline phosphatase, and serum creatinine) occurred with similar frequencies in the 2 groups.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ee0-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Genital Herpes</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ee1-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Initial Episode:</content>In a clinical trial for the treatment of initial episodes of genital herpes, the adverse reactions reported by greater than or equal to 5% of subjects receiving valacyclovir tablets 1 gram twice daily for 10 days (n = 318) or oral acyclovir 200 mg 5 times daily for 10 days (n = 318), respectively, included headache (13%, 10%) and nausea (6%, 6%). For the incidence of laboratory abnormalities see
 
  <linkHtml href="#tab2">Table 2</linkHtml>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ee2-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Recurrent Episodes:</content>In 3 clinical trials for the episodic treatment of recurrent genital herpes, the adverse reactions reported by greater than or equal to 5% of subjects receiving valacyclovir tablets 500 mg twice daily for 3 days (n = 402), valacyclovir tablets 500 mg twice daily for 5 days (n = 1,136) or placebo (n = 259), respectively, included headache (16%, 11%, 14%) and nausea (5%, 4%, 5%). For the incidence of laboratory abnormalities see
 
  <linkHtml href="#tab2">Table 2</linkHtml>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ee3-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Suppressive Therapy: Suppression of Recurrent Genital Herpes in Immunocompetent Adults:</content>In a clinical trial for the suppression of recurrent genital herpes infections, the adverse reactions reported by subjects receiving valacyclovir tablets 1 gram once daily (n = 269), valacyclovir tablets 500 mg once daily (n = 266), or placebo (n = 134), respectively, included headache (35%, 38%, 34%), nausea (11%, 11%, 8%), abdominal pain (11%, 9%, 6%), dysmenorrhea (8%, 5%, 4%), depression (7%, 5%, 5%), arthralgia (6%, 5%, 4%), vomiting (3%, 3%, 2%), and dizziness (4%, 2%, 1%). For the incidence of laboratory abnormalities see
 
  <linkHtml href="#tab2">Table 2</linkHtml>.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ee4-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Suppression of Recurrent Genital Herpes in HIV-1-Infected Subjects:</content>In HIV-1-infected subjects, frequently reported adverse reactions for valacyclovir tablets (500 mg twice daily; n = 194, median days on therapy = 172) and placebo (n = 99, median days on therapy = 59), respectively, included headache (13%, 8%), fatigue (8%, 5%), and rash (8%, 1%). Post-randomization laboratory abnormalities that were reported more frequently in valacyclovir subjects versus placebo included elevated alkaline phosphatase (4%, 2%), elevated ALT (14%, 10%), elevated AST (16%, 11%), decreased neutrophil counts (18%, 10%), and decreased platelet counts (3%, 0%), respectively.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ee5-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Reduction of Transmission:</content>In a clinical trial for the reduction of transmission of genital herpes, the adverse reactions reported by subjects receiving valacyclovir tablets 500 mg once daily (n = 743) or placebo once daily (n = 741), respectively, included headache (29%, 26%), nasopharyngitis (16%, 15%), and upper respiratory tract infection (9%, 10%).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ee6-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Herpes Zoster</content>
                              </paragraph>
                              <paragraph>In 2 clinical trials for the treatment of herpes zoster, the adverse reactions reported by subjects receiving valacyclovir tablets 1 gram 3 times daily for 7 to 14 days (n = 967) or placebo (n = 195), respectively, included nausea (15%, 8%), headache (14%, 12%), vomiting (6%, 3%), dizziness (3%, 2%), and abdominal pain (3%, 2%). For the incidence of laboratory abnormalities see
 
  <linkHtml href="#tab2">Table 2</linkHtml>.

 </paragraph>
                              <table width="90%" ID="tab2">
                                 <caption>Table 2. Incidence (%) of Laboratory Abnormalities in Herpes Zoster and Genital Herpes Trial Populations</caption>
                                 <col width="12%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <col width="11%" align="center" valign="middle"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th colspan="2" styleCode="Rrule">Herpes Zoster</th>
                                       <th colspan="3" styleCode="Rrule">Genital Herpes Treatment</th>
                                       <th colspan="3" styleCode="Rrule">Genital Herpes Suppression</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Laboratory Abnormality</th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  1 gram 
     <br/>  3 TimesDaily 
     <br/>  (n = 967)
    </th>
                                       <th styleCode="Rrule">Placebo 
     <br/>  (n = 195)
    </th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  1 gram 
     <br/>  Twice Daily 
     <br/>  (n = 1,194)
    </th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  500 mg 
     <br/>  Twice Daily 
     <br/>  (n = 1,159)
    </th>
                                       <th styleCode="Rrule">Placebo 
     <br/>  (n = 439)
    </th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  1 gram 
     <br/>  Once Daily 
     <br/>  (n = 269)
    </th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  500 mg 
     <br/>  Once Daily 
     <br/>  (n = 266)
    </th>
                                       <th styleCode="Rrule">Placebo 
     <br/>  (n = 134)
    </th>
                                    </tr>
                                 </thead>
                                 <tfoot>
                                    <tr>
                                       <td align="left" colspan="9" valign="top">LLN = Lower limit of normal.</td>
                                    </tr>
                                    <tr>
                                       <td align="left" colspan="9" valign="top">ULN = Upper limit of normal.</td>
                                    </tr>
                                 </tfoot>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Hemoglobin 
      <br/>  (&lt;0.8 × LLN)
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.8%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.3%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.2%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.8%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.8%</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">White blood cells 
      <br/>  (&lt;0.75 × LLN)
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.3%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.6%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.7%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.6%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.2%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.7%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.8%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.5%</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Platelet count 
      <br/>  (&lt;100,000/mm
     
      <sup>3</sup>)
    
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.2%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.3%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.1%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.7%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.4%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.1%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.5%</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">AST (SGOT) 
      <br/>  (&gt;2× ULN)
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">1.0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">
                                             <footnote ID="K2391">Data were not collected prospectively.</footnote>
                                          </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.5%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">4.1%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">3.8%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">3.0%</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Serum creatinine 
      <br/>  (&gt;1.5 × ULN)
     </content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.2%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0.7%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                       <td styleCode="Rrule">
                                          <content styleCode="bold">0%</content>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="3251e3f8-9ee7-fa19-e063-6394a90a31d1"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>6.2 Clinical Trials Experience in Pediatric Subjects</title>
                     <text>
                        <paragraph>The safety profile of valacyclovir tablets has been studied in 177 pediatric subjects aged 1 month to less than 18 years. Sixty-five of these pediatric subjects, aged 12 to less than 18 years, received oral tablets for 1 to 2 days for treatment of cold sores. The remaining 112 pediatric subjects, aged 1 month to less than 12 years, participated in 3 pharmacokinetic and safety trials and received valacyclovir oral suspension. Fifty-one of these 112 pediatric subjects received oral suspension for 3 to 6 days. The frequency, intensity, and nature of clinical adverse reactions and laboratory abnormalities were similar to those seen in adults.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ee8-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric Subjects Aged 12 to Less Than 18 Years (Cold Sores)</content>
                              </paragraph>
                              <paragraph>In clinical trials for the treatment of cold sores, the adverse reactions reported by adolescent subjects receiving valacyclovir tablets 2 grams twice daily for 1 day, or valacyclovir tablets 2 grams twice daily for 1 day followed by 1 gram twice daily for 1 day (n = 65, across both dosing groups), or placebo (n = 30), respectively, included headache (17%, 3%) and nausea (8%, 0%).</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ee9-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pediatric Subjects Aged 1 Month to Less Than 12 Years</content>
                              </paragraph>
                              <paragraph>Adverse events reported in more than 1 subject across the 3 pharmacokinetic and safety trials in children aged 1 month to less than 12 years were diarrhea (5%), pyrexia (4%), dehydration (2%), herpes simplex (2%), and rhinorrhea (2%). No clinically meaningful changes in laboratory values were observed.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.3">
                     <id root="3251e3f8-9eea-fa19-e063-6394a90a31d1"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.3 Postmarketing Experience</title>
                     <text>
                        <paragraph>In addition to adverse events reported from clinical trials, the following events have been identified during postmarketing use of valacyclovir tablets. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These events have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to valacyclovir tablets.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9eeb-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">General</content>
                              </paragraph>
                              <paragraph>Facial edema, hypertension, tachycardia.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9eec-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Allergic</content>
                              </paragraph>
                              <paragraph>Acute hypersensitivity reactions including anaphylaxis, angioedema, dyspnea, pruritus, rash, and urticaria
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S4">Contraindications (4)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9eed-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Central Nervous System (CNS) Symptoms</content>
                              </paragraph>
                              <paragraph>Aggressive behavior; agitation; ataxia; coma; confusion; decreased consciousness; dysarthria; encephalopathy; mania; and psychosis, including auditory and visual hallucinations, seizures, tremors
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>,
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9eee-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Eye</content>
                              </paragraph>
                              <paragraph>Visual abnormalities.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9eef-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Gastrointestinal</content>
                              </paragraph>
                              <paragraph>Diarrhea.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ef0-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hepatobiliary Tract and Pancreas</content>
                              </paragraph>
                              <paragraph>Liver enzyme abnormalities, hepatitis.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ef1-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Renal</content>
                              </paragraph>
                              <paragraph>Renal failure, renal pain (may be associated with renal failure)
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>,
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ef2-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hematologic</content>
                              </paragraph>
                              <paragraph>Thrombocytopenia, aplastic anemia, leukocytoclastic vasculitis, TTP/HUS
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].
 
  </content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9ef3-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Skin</content>
                              </paragraph>
                              <paragraph>Erythema multiforme, rashes including photosensitivity, alopecia.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="3251e3f8-9ef4-fa19-e063-6394a90a31d1"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>No clinically significant drug-drug or drug-food interactions with valacyclovir tablets are known
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230221"/>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="3251e3f8-9ef5-fa19-e063-6394a90a31d1"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20230221"/>
               <component>
                  <section ID="S8.1">
                     <id root="3251e3f8-9ef6-fa19-e063-6394a90a31d1"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9ef7-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Clinical data over several decades with valacyclovir and its metabolite, acyclovir, in pregnant women, have not identified a drug associated risk of major birth defects. There are insufficient data on the use of valacyclovir regarding miscarriage or adverse maternal or fetal outcomes
 
  <content styleCode="italics">(see
  
   <linkHtml href="#data">Data</linkHtml>).
 
  </content>There are risks to the fetus associated with untreated herpes simplex during pregnancy
 
  <content styleCode="italics">(see
  
   <linkHtml href="#clincon">Clinical Considerations</linkHtml>).
 
  </content>
                              </paragraph>
                              <paragraph>In animal reproduction studies, no evidence of adverse developmental outcomes was observed with valacyclovir when administered to pregnant rats and rabbits at system exposures (AUC) 4 (rats) and 7 (rabbits) times the human exposure at the maximum recommended human dose (MRHD) (see
 
  <linkHtml href="#data">Data</linkHtml>).

 </paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section ID="clincon">
                           <id root="3251e3f8-9ef8-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9ef9-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Disease-Associated Maternal and/or Embryo/Fetal Risk:</content>The risk of neonatal HSV infection varies from 30% to 50% for genital HSV acquired in late pregnancy (third trimester), whereas with HSV acquisition in early pregnancy, the risk of neonatal infection is about 1%. A primary herpes occurrence during the first trimester of pregnancy has been associated with neonatal chorioretinitis, microcephaly, and, in rare cases, skin lesions. In very rare cases, transplacental transmission can occur resulting in congenital infection, including microcephaly, hepatosplenomegaly, intrauterine growth restriction, and stillbirth. Co-infection with HSV increases the risk of perinatal HIV transmission in women who had a clinical diagnosis of genital herpes during pregnancy.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="3251e3f8-9efa-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9efb-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data:</content>Clinical data over several decades with valacyclovir and its metabolite, acyclovir, in pregnant women, based on published literature, have not identified a drug-associated risk of major birth defects. There are insufficient data on the use of valacyclovir regarding miscarriage or adverse maternal or fetal outcomes. The Acyclovir and the Valacyclovir Pregnancy Registries, both population-based international prospective studies, collected pregnancy data through April 1999. The Acyclovir Registry documented outcomes of 1,246 infants and fetuses exposed to acyclovir during pregnancy (756 with earliest exposure during the first trimester, 197 during the second trimester, 291 during the third trimester, and 2 unknown). The occurrence of major birth defects during first-trimester exposure to acyclovir was 3.2% (95% CI: 2.0% to 5.0%) and during any trimester of exposure was 2.6% (95% CI: 1.8% to 3.8%). The Valacyclovir Pregnancy Registry documented outcomes of 111 infants and fetuses exposed to valacyclovir during pregnancy (28 with earliest exposure in the first trimester, 31 during the second trimester, and 52 during the third trimester).The occurrence of major birth defects during first-trimester exposure to valacyclovir was 4.5% (95% CI: 0.24% to 24.9%) and during any trimester of exposure was 3.9% (95% CI: 1.3% to 10.7%).

 </paragraph>
                                    <paragraph>Available studies have methodological limitations including insufficient sample size to support conclusions about overall malformation risk or for making comparisons of the frequencies of specific birth defects.</paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9efc-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data:</content>Valacyclovir was administered orally to pregnant rats and rabbits (up to 400 mg/kg/day) during organogenesis (Gestation Days 6 through 15, and 6 through 18, respectively). No adverse embryo-fetal effects were observed in rats and rabbits at acyclovir exposures (AUC) of up to approximately 4 (rats) and 7 (rabbits) times the exposure in humans at the MRHD. Early embryo death, fetal growth retardation (weight and length), and variations in fetal skeletal development (primarily extra ribs and delayed ossification of sternebrae) were observed in rats and associated with maternal toxicity (200 mg/kg/day; approximately 6 times higher than human exposure at the MRHD).

 </paragraph>
                                    <paragraph>In a pre/postnatal development study, valacyclovir was administered orally to pregnant rats (up to 200 mg/kg/day from Gestation Day 15 to Post-Partum Day 20) from late gestation through lactation. No significant adverse effects were observed in offspring exposed daily from before birth through lactation at maternal exposures (AUC) of approximately 6 times higher than human exposures at the MRHD.</paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="3251e3f8-9efd-fa19-e063-6394a90a31d1"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9efe-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Although there is no information on the presence of valacyclovir in human milk, its metabolite, acyclovir, is present in human milk following oral administration of valacyclovir. Based on published data, a 500-mg maternal dose of valacyclovir tablets twice daily would provide a breastfed child with an oral acyclovir dosage of approximately 0.6 mg/kg/day (see
 
  <linkHtml href="#data">Data</linkHtml>). There is no data on the effects of valacyclovir or acyclovir on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for valacyclovir tablets and any potential adverse effects on the breastfed child from valacyclovir tablets or from the underlying maternal condition.

 </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9eff-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                              <paragraph>Following oral administration of a 500-mg dose of valacyclovir tablets to 5 lactating women, peak acyclovir concentrations (C
 
  <sub>max</sub>) in breast milk ranged from 0.5 to 2.3 times (median 1.4) the corresponding maternal acyclovir serum concentrations. The acyclovir breast milk AUC ranged from 1.4 to 2.6 times (median 2.2) maternal serum AUC. A 500-mg maternal dose of valacyclovir tablets twice daily would provide a breastfed child with an oral acyclovir dosage of approximately 0.6 mg/kg/day. Unchanged valacyclovir was not detected in maternal serum, breast milk or infant urine.

 </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="3251e3f8-9f00-fa19-e063-6394a90a31d1"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Valacyclovir tablets are indicated for treatment of cold sores in pediatric patients aged greater than or equal to 12 years and for treatment of chickenpox in pediatric patients aged 2 to less than 18 years
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S1.2">Indications and Usage (1.2)</linkHtml>,
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>The use of valacyclovir tablets for treatment of cold sores is based on 2 double-blind, placebo-controlled clinical trials in healthy adults and adolescents (aged greater than or equal to 12 years) with a history of recurrent cold sores
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>The use of valacyclovir tablets for treatment of chickenpox in pediatric patients aged 2 to less than 18 years is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by efficacy and safety data from 3 randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric subjects with chickenpox
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>,
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>,
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>The efficacy and safety of valacyclovir have not been established in pediatric patients:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>aged less than 12 years with cold sores</item>
                           <item>aged less than 18 years with genital herpes</item>
                           <item>aged less than 18 years with herpes zoster</item>
                           <item>aged less than 2 years with chickenpox</item>
                           <item>for suppressive therapy following neonatal HSV infection.</item>
                        </list>
                        <paragraph>The pharmacokinetic profile and safety of valacyclovir oral suspension in children aged less than 12 years were studied in 3 open label trials. No efficacy evaluations were conducted in any of the 3 trials.</paragraph>
                        <paragraph>Trial 1 was a single dose pharmacokinetic, multiple dose safety trial in 27 pediatric subjects aged 1 to less than 12 years with clinically suspected varicella-zoster virus (VZV) infection
 
  <content styleCode="italics">[see
  
   <linkHtml href="#s2.2">Dosage and Administration (2.2)</linkHtml>,
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>,
  
   <linkHtml href="#S14.4">Clinical Studies (14.4)</linkHtml>].
 
  </content>
                        </paragraph>
                        <paragraph>Trial 2 was a single-dose pharmacokinetic and safety trial in pediatric subjects aged 1 month to less than 6 years who had an active herpes virus infection or who were at risk for herpes virus infection. Fifty-seven subjects were enrolled and received a single dose of 25 mg/kg valacyclovir oral suspension. In infants and children aged 3 months to less than 6 years, this dose provided comparable systemic acyclovir exposures to that from a 1-gram dose of valacyclovir in adults (historical data). In infants aged 1 month to less than 3 months, mean acyclovir exposures resulting from a 25-mg/kg dose were higher (C
 
  <sub>max</sub>: ↑30%, AUC: ↑60%) than acyclovir exposures following a 1-gram dose of valacyclovir in adults. Acyclovir is not approved for suppressive therapy in infants and children following neonatal HSV infections; therefore valacyclovir is not recommended for this indication because efficacy cannot be extrapolated from acyclovir.

 </paragraph>
                        <paragraph>Trial 3 was a single-dose pharmacokinetic, multiple-dose safety trial in 28 pediatric subjects aged 1 to less than 12 years with clinically suspected HSV infection. None of the subjects enrolled in this trial had genital herpes. Each subject was dosed with valacyclovir oral suspension, 10 mg/kg twice daily for 3 to 5 days. Acyclovir systemic exposures in pediatric subjects following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of recurrent genital herpes. The mean projected daily acyclovir systemic exposures in pediatric subjects across all age groups (1 to less than 12 years) were lower (C
 
  <sub>max</sub>: ↓20%, AUC: ↓33%) compared with the acyclovir systemic exposures in adults receiving valacyclovir 500 mg twice daily, but were higher (daily AUC: ↑16%) than systemic exposures in adults receiving acyclovir 200 mg 5 times daily. Insufficient data are available to support valacyclovir for the treatment of recurrent genital herpes in this age-group because clinical information on recurrent genital herpes in young children is limited; therefore, extrapolating efficacy data from adults to this population is not possible. Moreover, valacyclovir has not been studied in children aged 1 to less than 12 years with recurrent genital herpes.

 </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="3251e3f8-9f01-fa19-e063-6394a90a31d1"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the total number of subjects in clinical trials of valacyclovir tablets, 906 were 65 and over, and 352 were 75 and over. In a clinical trial of herpes zoster, the duration of pain after healing (post-herpetic neuralgia) was longer in subjects 65 and older compared with younger adults. Elderly patients are more likely to have reduced renal function and require dose reduction. Elderly patients are also more likely to have renal or CNS adverse events
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>,
  
   <linkHtml href="#S5.3">5.3)</linkHtml>,
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="3251e3f8-9f02-fa19-e063-6394a90a31d1"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Dosage reduction is recommended when administering valacyclovir tablets to patients with renal impairment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
  
   <linkHtml href="#S5.2">Warnings and Precautions (5.2</linkHtml>,
  
   <linkHtml href="#S5.3">5.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="3251e3f8-9f03-fa19-e063-6394a90a31d1"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Caution should be exercised to prevent inadvertent overdose
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>].
 
  </content>Precipitation of acyclovir in renal tubules may occur when the solubility (2.5 mg/mL) is exceeded in the intratubular fluid. In the event of acute renal failure and anuria, the patient may benefit from hemodialysis until renal function is restored
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20230221"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="3251e3f8-9f04-fa19-e063-6394a90a31d1"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Valacyclovir Tablets, USP is the hydrochloride salt of the
 
  <content styleCode="italics">L</content>-valyl ester of the antiviral drug acyclovir.

 </paragraph>
                  <paragraph>Valacyclovir Tablets, USP are for oral administration. Each tablet contains 556.2 mg or 1.112 grams of valacyclovir hydrochloride equivalent to 500 mg or 1 gram of valacyclovir, respectively, and the inactive ingredients anhydrous dibasic calcium phosphate, colloidal silicon dioxide, croscarmellose sodium, FD&amp;C blue #2, hypromellose, magnesium stearate, polyethylene glycol 400, polysorbate 80, povidone K90, and titanium dioxide.</paragraph>
                  <paragraph>The chemical name of valacyclovir hydrochloride is
 
  <content styleCode="italics">L</content>-valine, 2-[(2-amino-1,6-dihydro-6-oxo-9
 
  <content styleCode="italics">H</content>-purin-9-yl)methoxy]ethyl ester, monohydrochloride. It has the following structural formula:

 </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Valacyclovir hydrochloride is a white to off-white powder with the molecular formula C
 
  <sub>13</sub>H
 
  <sub>20</sub>N
 
  <sub>6</sub>O
 
  <sub>4</sub>∙HCl and a molecular weight of 360.80. The maximum solubility in water at 25°C is 174 mg/mL. The pkas for valacyclovir hydrochloride are 1.90, 7.47, and 9.43.

 </paragraph>
               </text>
               <effectiveTime value="20230221"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="valacyclovir-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="3251e3f8-9f05-fa19-e063-6394a90a31d1"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20230221"/>
               <component>
                  <section ID="S12.1">
                     <id root="3251e3f8-9f06-fa19-e063-6394a90a31d1"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Valacyclovir is an antiviral drug active against α-herpes viruses
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.4">Microbiology (12.4)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="3251e3f8-9f07-fa19-e063-6394a90a31d1"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of valacyclovir and acyclovir after oral administration of valacyclovir tablets have been investigated in 14 volunteer trials involving 283 adults and in 3 trials involving 112 pediatric subjects aged 1 month to less than 12 years.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9f08-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pharmacokinetics in Adults</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f09-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Absorption and Bioavailability:</content>After oral administration, valacyclovir hydrochloride is rapidly absorbed from the gastrointestinal tract and nearly completely converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism.

 </paragraph>
                                    <paragraph>The absolute bioavailability of acyclovir after administration of valacyclovir tablets is 54.5% ± 9.1% as determined following a 1-gram oral dose of valacyclovir tablets and a 350-mg intravenous acyclovir dose to 12 healthy volunteers. Acyclovir bioavailability from the administration of valacyclovir tablets is not altered by administration with food (30 minutes after an 873 Kcal breakfast, which included 51 grams of fat).</paragraph>
                                    <paragraph>Acyclovir pharmacokinetic parameter estimates following administration of valacyclovir tablets to healthy adult volunteers are presented in Table 3. There was a less than dose-proportional increase in acyclovir maximum concentration (C
 
  <sub>max</sub>) and area under the acyclovir concentration-time curve (AUC) after single-dose and multiple-dose administration (4 times daily) of valacyclovir tablets from doses between 250 mg to 1 gram.

 </paragraph>
                                    <paragraph>There is no accumulation of acyclovir after the administration of valacyclovir at the recommended dosage regimens in adults with normal renal function.</paragraph>
                                    <table width="80%">
                                       <caption>Table 3. Mean (±SD) Plasma Acyclovir Pharmacokinetic Parameters Following Administration of Valacyclovir Tablets to Healthy Adult Volunteers</caption>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule Botrule">Dose</th>
                                             <th colspan="2" styleCode="Rrule Botrule">Single-Dose Administration (N = 8)</th>
                                             <th colspan="2" align="left" styleCode="Rrule Botrule">Multiple-Dose Administration
    
     <footnote ID="K3346">Administered 4 times daily for 11 days.</footnote>(N = 24, 8 per treatment arm)
   
    </th>
                                          </tr>
                                          <tr>
                                             <th styleCode="Lrule Rrule"/>
                                             <th styleCode="Rrule">Cmax (±SD) (mcg/mL)</th>
                                             <th styleCode="Rrule">AUC (±SD)(h∙mcg/mL)</th>
                                             <th styleCode="Rrule">Cmax (±SD) (mcg/mL)</th>
                                             <th styleCode="Rrule">AUC (±SD)(h∙mcg/mL)</th>
                                          </tr>
                                       </thead>
                                       <tfoot>
                                          <tr>
                                             <td align="left" colspan="5" valign="top">ND = not done.</td>
                                          </tr>
                                       </tfoot>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">100 mg</td>
                                             <td styleCode="Rrule">0.83 (±0.14)</td>
                                             <td styleCode="Rrule">2.28 (±0.40)</td>
                                             <td styleCode="Rrule">ND</td>
                                             <td styleCode="Rrule">ND</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">250 mg</td>
                                             <td styleCode="Rrule">2.15 (±0.50)</td>
                                             <td styleCode="Rrule">5.76 (±0.60)</td>
                                             <td styleCode="Rrule">2.11 (±0.33)</td>
                                             <td styleCode="Rrule">5.66 (±1.09)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">500 mg</td>
                                             <td styleCode="Rrule">3.28 (±0.83)</td>
                                             <td styleCode="Rrule">11.59 (±1.79)</td>
                                             <td styleCode="Rrule">3.69 (±0.87)</td>
                                             <td styleCode="Rrule">9.88 (±2.01)</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">750 mg</td>
                                             <td styleCode="Rrule">4.17 (±1.14)</td>
                                             <td styleCode="Rrule">14.11 (±3.54)</td>
                                             <td styleCode="Rrule">ND</td>
                                             <td styleCode="Rrule">ND</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">1,000 mg</td>
                                             <td styleCode="Rrule">5.65 (±2.37)</td>
                                             <td styleCode="Rrule">19.52 (±6.04)</td>
                                             <td styleCode="Rrule">4.96 (±0.64)</td>
                                             <td styleCode="Rrule">15.70 (±2.27)</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f0a-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Distribution:</content>The binding of valacyclovir to human plasma proteins ranges from 13.5% to 17.9%. The binding of acyclovir to human plasma proteins ranges from 9% to 33%.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f0b-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism:</content>Valacyclovir is converted to acyclovir and L-valine by first-pass intestinal and/or hepatic metabolism.

 </paragraph>
                                    <paragraph>Acyclovir is converted to a small extent to inactive metabolites by aldehyde oxidase and by alcohol and aldehyde dehydrogenase. Neither valacyclovir nor acyclovir is metabolized by cytochrome P450 enzymes. Plasma concentrations of unconverted valacyclovir are low and transient, generally becoming non-quantifiable by 3 hours after administration. Peak plasma valacyclovir concentrations are generally less than 0.5 mcg/mL at all doses. After single-dose administration of 1 gram of valacyclovir tablets, average plasma valacyclovir concentrations observed were 0.5, 0.4, and 0.8 mcg/mL in subjects with hepatic dysfunction, renal insufficiency, and in healthy subjects who received concomitant cimetidine and probenecid, respectively.</paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f0c-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Elimination:</content>The pharmacokinetic disposition of acyclovir delivered by valacyclovir is consistent with previous experience from intravenous and oral acyclovir. Following the oral administration of a single 1-gram dose of radiolabeled valacyclovir to 4 healthy subjects, 46% and 47% of administered radioactivity was recovered in urine and feces, respectively, over 96 hours. Acyclovir accounted for 89% of the radioactivity excreted in the urine. Renal clearance of acyclovir following the administration of a single 1-gram dose of valacyclovir tablets to 12 healthy subjects was approximately 255 ± 86 mL/min which represents 42% of total acyclovir apparent plasma clearance.

 </paragraph>
                                    <paragraph>The plasma elimination half-life of acyclovir typically averaged 2.5 to 3.3 hours in all trials of valacyclovir tablets in subjects with normal renal function.</paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f0d-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f0e-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Renal Impairment:</content>Reduction in dosage is recommended in patients with renal impairment
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>,
  
   <linkHtml href="#S8.6">8.6)</linkHtml>].
 
  </content>
                                    </paragraph>
                                    <paragraph>Following administration of valacyclovir tablets to subjects with ESRD, the average acyclovir half-life is approximately 14 hours. During hemodialysis, the acyclovir half-life is approximately 4 hours. Approximately one-third of acyclovir in the body is removed by dialysis during a 4-hour hemodialysis session. Apparent plasma clearance of acyclovir in subjects on dialysis was 86.3 ± 21.3 mL/min/1.73 m
 
  <sup>2</sup>compared with 679.16 ± 162.76 mL/min/1.73 m
 
  <sup>2</sup>in healthy subjects.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f0f-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with Hepatic Impairment:</content>Administration of valacyclovir tablets to subjects with moderate (biopsy-proven cirrhosis) or severe (with and without ascites and biopsy-proven cirrhosis) liver disease indicated that the rate but not the extent of conversion of valacyclovir to acyclovir is reduced, and the acyclovir half-life is not affected. Dosage modification is not recommended for patients with cirrhosis.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f10-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Patients with HIV-1 Disease:</content>In 9 subjects with HIV-1 disease and CD4+ cell counts less than 150 cells/mm
 
  <sup>3</sup>who received valacyclovir tablets at a dosage of 1 gram 4 times daily for 30 days, the pharmacokinetics of valacyclovir and acyclovir were not different from that observed in healthy subjects.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f11-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Geriatrics Patients:</content>After single-dose administration of 1 gram of valacyclovir tablets in healthy geriatric subjects, the half-life of acyclovir was 3.11 ± 0.51 hours, compared with 2.91 ± 0.63 hours in healthy younger adult subjects. The pharmacokinetics of acyclovir following single- and multiple-dose oral administration of valacyclovir tablets in geriatric subjects varied with renal function. Dose reduction may be required in geriatric patients, depending on the underlying renal status of the patient
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>,
  
   <linkHtml href="#S8.5">Use in Specific Populations (8.5</linkHtml>.
  
   <linkHtml href="#S8.6">8.6)</linkHtml>].
 
  </content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f12-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Pediatrics Patients:</content>Acyclovir pharmacokinetics have been evaluated in a total of 98 pediatric subjects (aged 1 month to less than 12 years) following administration of the first dose of an extemporaneous oral suspension of valacyclovir
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S6.2">Adverse Reactions (6.2)</linkHtml>,
  
   <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>].
 
  </content>Acyclovir pharmacokinetic parameter estimates following a 20-mg/kg dose are provided in Table 4.

 </paragraph>
                                    <table width="75%">
                                       <caption>Table 4. Mean (±SD) Plasma Acyclovir Pharmacokinetic Parameter Estimates Following First-Dose Administration of 20 mg/kg Valacyclovir Oral Suspension to Pediatric Subjects vs. 1-Gram Single Dose of Valacyclovir Tablets to Adults</caption>
                                       <col width="20%" align="left" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="center" valign="top"/>
                                       <col width="20%" align="left" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th align="left" rowspan="2" styleCode="Lrule Rrule" valign="middle">Parameter</th>
                                             <th colspan="3" styleCode="Rrule Botrule" valign="middle">Pediatric Subjects(20 mg/kg Oral Suspension)</th>
                                             <th rowspan="2" styleCode="Rrule">Adults 
     <br/>  1-gram Solid Dose of Valacyclovir Tablets
    
     <footnote ID="K3699">Historical estimates using pediatric pharmacokinetic sampling schedule.</footnote>(N = 15)
   
    </th>
                                          </tr>
                                          <tr>
                                             <th align="center" styleCode="Rrule">1 -&lt;2 year(N = 6)</th>
                                             <th styleCode="Rrule">2 -&lt;6 year(N = 12)</th>
                                             <th styleCode="Rrule">6 -&lt;12 year(N = 8)</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr>
                                             <td align="center" styleCode="Lrule Rrule">AUC (mcg∙h/mL) 
     <br/>  C
    
     <sub>max</sub>(mcg/mL)
   
    </td>
                                             <td styleCode="Rrule">14.4 (±6.26) 
     <br/>  4.03 (±1.37)
    </td>
                                             <td styleCode="Rrule">10.1 (±3.35) 
     <br/>  3.75 (±1.14
    
     <content styleCode="bold">)</content>
                                             </td>
                                             <td styleCode="Rrule">13.1 (±3.43) 
     <br/>  4.71 (±1.20)
    </td>
                                             <td styleCode="Rrule">17.2 (±3.10) 
     <br/>  4.72 (±1.37)
    </td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f13-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interactions Studies</content>
                              </paragraph>
                              <paragraph>When valacyclovir tablets is coadministered with antacids, cimetidine and/or probenecid, digoxin, or thiazide diuretics in patients with normal renal function, the effects are not considered to be of clinical significance (see below). Therefore, when valacyclovir tablets is coadministered with these drugs in patients with normal renal function, no dosage adjustment is recommended.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f14-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Antacids:</content>The pharmacokinetics of acyclovir after a single dose of valacyclovir tablets (1 gram) were unchanged by coadministration of a single dose of antacids (Al
 
  <sup>3</sup>+ or Mg
 
  <sup>++</sup>).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f15-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>Cimetidine: Acyclovir C
 
  <sub>max</sub>and AUC following a single dose of valacyclovir tablets (1 gram) increased by 8% and 32%, respectively, after a single dose of cimetidine (800 mg).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f16-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Cimetidine Plus Probenecid:</content>Acyclovir C
 
  <sub>max</sub>and AUC following a single dose of valacyclovir tablets (1 gram) increased by 30% and 78%, respectively, after a combination of cimetidine and probenecid, primarily due to a reduction in renal clearance of acyclovir.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f17-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Digoxin:</content>The pharmacokinetics of digoxin were not affected by coadministration of valacyclovir tablets 1 gram 3 times daily, and the pharmacokinetics of acyclovir after a single dose of valacyclovir tablets (1 gram) was unchanged by coadministration of digoxin (2 doses of 0.75 mg).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f18-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Probenecid:</content>Acyclovir C
 
  <sub>max</sub>and AUC following a single dose of valacyclovir tablets (1 gram) increased by 22% and 49%, respectively, after probenecid (1 gram).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f19-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Thiazide Diuretics:</content>The pharmacokinetics of acyclovir after a single dose of valacyclovir tablets (1 gram) were unchanged by coadministration of multiple doses of thiazide diuretics.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.4">
                     <id root="3251e3f8-9f1a-fa19-e063-6394a90a31d1"/>
                     <code code="49489-8" codeSystem="2.16.840.1.113883.6.1" displayName="MICROBIOLOGY SECTION"/>
                     <title>12.4 Microbiology</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9f1b-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mechanism of Action</content>
                              </paragraph>
                              <paragraph>Valacyclovir is a deoxynucleoside analogue DNA polymerase inhibitor. Valacyclovir hydrochloride is rapidly converted to acyclovir, which has demonstrated antiviral activity against HSV types 1 (HSV-1) and 2 (HSV-2) and VZV both in cell culture and in vivo.</paragraph>
                              <paragraph>Acyclovir is a synthetic purine deoxynucleoside that is phosphorylated intracellularly by the viral encoded thymidine kinase (TK; pUL23) of HSV or VZV into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. In biochemical assays, acyclovir triphosphate inhibits replication of α-herpes viral DNA. This is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared with VZV is due to its more efficient phosphorylation by the viral TK.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f1c-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Antiviral Activities</content>
                              </paragraph>
                              <paragraph>The quantitative relationship between the cell culture susceptibility of herpesviruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (EC
 
  <sub>50</sub>), vary greatly depending upon a number of factors. Using plaque-reduction assays, the EC
 
  <sub>50</sub>values against herpes simplex virus isolates range from 0.09 to 60 microM (0.02 to 13.5 mcg/mL) for HSV-1 and from 0.04 to 44 microM (0.01 to 9.9 mcg/mL) for HSV-2. The EC
 
  <sub>50</sub>values for acyclovir against most laboratory strains and clinical isolates of VZV range from 0.53 to 48 microM (0.12 to 10.8 mcg/mL). Acyclovir also demonstrates activity against the Oka vaccine strain of VZV with a mean EC
 
  <sub>50</sub>of 6 microM (1.35 mcg/mL).

 </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f1d-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Resistance</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f1e-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Cell Culture:</content>Acyclovir-resistant HSV-1, HSV-2, and VZV strains were isolated in cell culture. Acyclovir-resistant HSV and VZV resulted from mutations in the viral thymidine kinase (TK, pUL23) and DNA polymerase (POL; pUL30) genes. Frameshifts were commonly isolated and result in premature truncation of the HSV TK product with consequent decreased susceptibility to acyclovir. Mutations in the viral TK gene may lead to complete loss of TK activity (TK negative), reduced levels of TK activity (TK partial), or alteration in the ability of viral TK to phosphorylate the drug without an equivalent loss in the ability to phosphorylate thymidine (TK altered). In cell culture, acyclovir resistance-associated substitutions in TK of HSV-1 and HSV-2 were observed (Table 5).

 </paragraph>
                                    <table width="75%">
                                       <caption>Table 5. Summary of Acyclovir Resistance-Associated Amino Acid Substitutions in Cell Culture</caption>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="70%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Virus</th>
                                             <th styleCode="Rrule">Gene</th>
                                             <th styleCode="Rrule">Substitution</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HSV-1</td>
                                             <td styleCode="Rrule">TK</td>
                                             <td styleCode="Rrule">P5A, H7Q, L50V, G56V, G59R/V/W/A, G61A/V, K62I/N, T63A, E83K, P84L/S, R89W, D116N, P131S, P155R, F161I/C, R163H/P, A167V, P173L, R176Q/W, Q185R, A189L/V, G200S, G206R, R216S, R220H, L227F, Y239S, T245M, Q261stop, R281stop, T287M, M322K, C336Y, V348A</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HSV-2</td>
                                             <td styleCode="Rrule">TK</td>
                                             <td styleCode="Rrule">L69P, C172R, A175V, T288M</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HSV-1</td>
                                             <td styleCode="Rrule">POL</td>
                                             <td styleCode="Rrule">D368A, Y557S, E597D, V621S, L702H, A719V, S742N, N815S, V817M, Y818C, G841C/S</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">HSV-2</td>
                                             <td styleCode="Rrule">POL</td>
                                             <td styleCode="Rrule">No substitutions detected</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="3251e3f8-9f1f-fa19-e063-6394a90a31d1"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">HSV-Infected Patients:</content>Clinical HSV-1 and HSV-2 isolates obtained from patients who failed treatment for their α-herpes virus infections were evaluated for genotypic changes in the TK and POL genes and for phenotypic resistance to acyclovir (Table 6). HSV isolates with frameshift mutations and resistance-associated substitutions in TK and POL were identified. The listing of substitutions in the HSV TK and POL leading to decreased susceptibility to acyclovir is not all inclusive and additional changes will likely be identified in HSV variants isolated from patients who fail acyclovir-containing regimens. The possibility of viral resistance to acyclovir should be considered in patients who fail to respond or experience recurrent viral shedding during therapy.

 </paragraph>
                                    <table width="75%">
                                       <caption>Table 6. Summary of Acyclovir Resistance-Associated Amino Acid Substitutions Observed in Treated Patients</caption>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="15%" align="center" valign="top"/>
                                       <col width="70%" align="center" valign="top"/>
                                       <thead>
                                          <tr>
                                             <th styleCode="Lrule Rrule">Virus</th>
                                             <th styleCode="Rrule">Gene</th>
                                             <th styleCode="Rrule">Substitution</th>
                                          </tr>
                                       </thead>
                                       <tbody>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HSV-1</td>
                                             <td styleCode="Rrule">TK</td>
                                             <td styleCode="Rrule">G6C, R32H, R41H, R51W, Y53C/D/H, Y53stop, D55N, G56D/E/S, P57H, G58N/R, G59R, G61A/E/W, K62N, T63I, Q67stop, S74stop, Y80N, E83K, P84L, Y87H, E95stop, T103P, Q104H, Q104stop, H105P, M121K/L/R, Q125N, M128L, G129D, I143V, A156V, D162A/H/N, R163G/H, L170P, Y172C, P173L/R, A174P, A175V, R176Q/W, R176stop, L178R, S181N, A186P, V187M, A189V, V192A, G200C/D/S, T201P, T202A, V204G, A207P, L208F/H, R216C/H, R220C/H, R221C/H, R222C/H, E226K, D229H, L242P, T245M/P, L249P, Q250stop, C251G, E257K, Q261R, A265T, R281stop, T287M, L288stop, L291R, L297S, L315S, L327R, C336Y, C336stop, Q342stop, T354P, L364P, A365T</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HSV-2</td>
                                             <td styleCode="Rrule">TK</td>
                                             <td styleCode="Rrule">G25A, R34C, G39E, R51W, Y53N/D, G59P, G61A/E/W, S66P, A72S, D78N, P85S, R86P, A94V, L98stop, N100H, I101S, Q103stop, Q105P, A125T, T131P, Y133F, D137stop, F140L, L158P, S169P, R177W, S182N, M183Istop, V192M, G201D, R217H, R221C/H, Q222stop, R223H, D229stop, Y239stop, D231N, L263stop, R271V, P272S, D273R, T287M, C337Y</td>
                                          </tr>
                                          <tr styleCode="Botrule">
                                             <td styleCode="Lrule Rrule">HSV-1</td>
                                             <td styleCode="Rrule">POL</td>
                                             <td styleCode="Rrule">K532T, S559L, Q570R, L583V, A605V, V621S, A657T, D672N, V715G, A719T/V, S724N, F733C, E771Q, S775N, L778M, E798K, V813M, N815S, G841S, R842S, I890M, V958L, H1228D</td>
                                          </tr>
                                          <tr>
                                             <td styleCode="Lrule Rrule">HSV-2</td>
                                             <td styleCode="Rrule">POL</td>
                                             <td styleCode="Rrule">E250Q, D307N, K533E, A606V, C625R, R628C, E678G, A724V, S725G, S729N, I731F, Q732R, D785N, M789K/T, V818A, N820S, Y823C, Q829R, T843A, M910T, D912N/V, A915V, F923L, T934A, R964H</td>
                                          </tr>
                                       </tbody>
                                    </table>
                                    <paragraph>Note: Many additional pathways to acyclovir resistance likely exist.</paragraph>
                                 </text>
                                 <effectiveTime value="20230221"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f20-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cross-Resistance</content>
                              </paragraph>
                              <paragraph>Cross-resistance has been observed among HSV isolates carrying frameshift mutations and resistance-associated substitutions, which confer reduced susceptibility to penciclovir (PCV), famciclovir (FCV), and foscarnet (FOS) (Table 7).</paragraph>
                              <table width="75%">
                                 <caption>Table 7. Summary of Acyclovir Resistance-Associated Amino Acid Substitutions Conferring Cross-Resistance to PCV, FCV or FOS</caption>
                                 <col width="20%" align="center" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="65%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Cross-Resistant Drug</th>
                                       <th styleCode="Rrule">Virus/Gene</th>
                                       <th styleCode="Rrule">Substitution</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td rowspan="4" styleCode="Lrule Rrule Botrule">PCV/FCV</td>
                                       <td styleCode="Rrule Botrule">HSV-1 TK</td>
                                       <td styleCode="Rrule Botrule">G6C, R32H, R51W, Y53C/H/N, H58N, G61A, S74stop, E83K, P84L, T103P, Q104stop, D116N, M121R, I143V, P155R, R163G/H, A167V, L170P, Y172C, P173L, A174P, R176Q/W, Q185R, A186P, A189L/V, G200D/S, G206R, L208H, R216C, R220H, R222C/H, Y239S, T245M, Q250stop, Q261stop, R281stop, T287M, L315S, M322K, C336Y, V348A</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule">HSV-1 POL</td>
                                       <td styleCode="Rrule Botrule">A657T, D672N, V715G, A719V, S724N, E798K, N815S, G841C/S</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule">HSV-2 TK</td>
                                       <td styleCode="Rrule Botrule">G39E, R51W, Y53N, R86P, Y133F, R177W, R221H, T288M</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule Botrule">HSV-2 POL</td>
                                       <td styleCode="Rrule Botrule">K533E, A606V, C625R, R628C, S729N, Q732R, M789K/T, V818A, N820S, F923L, T934A</td>
                                    </tr>
                                    <tr>
                                       <td rowspan="2" styleCode="Lrule Rrule Botrule">FOS</td>
                                       <td styleCode="Rrule Botrule" valign="middle">HSV-1 POL</td>
                                       <td styleCode="Rrule Botrule" valign="middle">D368A, A605V, D672N, L702H, V715G, A719T/V, S724N, L778M, E798K, V813M, N815S, V817M, G841C/S, I890M</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Rrule" valign="middle">HSV-2 POL</td>
                                       <td styleCode="Rrule" valign="middle">K533E, A606V, C625R, R628C, A724V, S725G, S729N, I731F, Q732R, M789K/T, V818A, Y823C, D912V, F923L, T934A, R964H</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="3251e3f8-9f21-fa19-e063-6394a90a31d1"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20230221"/>
               <component>
                  <section ID="S13.1">
                     <id root="3251e3f8-9f22-fa19-e063-6394a90a31d1"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>The data presented below include references to the steady-state acyclovir AUC observed in humans treated with 1-gram of valacyclovir tablets given orally 3 times a day to treat herpes zoster. Plasma drug concentrations in animal studies are expressed as multiples of human exposure to acyclovir
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9f23-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Valacyclovir was noncarcinogenic in lifetime carcinogenicity bioassays at single daily doses (gavage) of valacyclovir giving plasma acyclovir concentrations equivalent to human levels in the mouse bioassay and 1.4 to 2.3 times human levels in the rat bioassay. There was no significant difference in the incidence of tumors between treated and control animals, nor did valacyclovir shorten the latency of tumors.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f24-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Valacyclovir was tested in 5 genetic toxicity assays. An Ames assay was negative in the absence or presence of metabolic activation. Also negative were an in vitro cytogenetic study with human lymphocytes and a rat cytogenetic study.</paragraph>
                              <paragraph>In the mouse lymphoma assay, valacyclovir was not mutagenic in the absence of metabolic activation. In the presence of metabolic activation (76% to 88% conversion to acyclovir), valacyclovir was mutagenic.</paragraph>
                              <paragraph>Valacyclovir was mutagenic in a mouse micronucleus assay.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f25-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Valacyclovir did not impair fertility or reproduction in male or female rats at acyclovir exposures (AUC) 6 times higher than in humans given the MRHD. Testicular atrophy occurred in male rats (orally dosed for 97 days at 18 times the MRHD) and was reversible.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="3251e3f8-9f26-fa19-e063-6394a90a31d1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20230221"/>
               <component>
                  <section ID="S14.1">
                     <id root="3251e3f8-9f27-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Cold Sores (Herpes Labialis )</title>
                     <text>
                        <paragraph>Two double-blind, placebo-controlled clinical trials were conducted in 1,856 healthy adults and adolescents (aged greater than or equal to 12 years) with a history of recurrent cold sores. Subjects self-initiated therapy at the earliest symptoms and prior to any signs of a cold sore. The majority of subjects initiated treatment within 2 hours of onset of symptoms. Subjects were randomized to valacyclovir tablets 2 grams twice daily on Day 1 followed by placebo on Day 2, valacyclovir tablets 2 grams twice daily on Day 1 followed by 1 gram twice daily on Day 2, or placebo on Days 1 and 2.</paragraph>
                        <paragraph>The mean duration of cold sore episodes was about 1 day shorter in treated subjects as compared with placebo. The 2-day regimen did not offer additional benefit over the 1-day regimen.</paragraph>
                        <paragraph>No significant difference was observed between subjects receiving valacyclovir tablets or placebo in the prevention of progression of cold sore lesions beyond the papular stage.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="3251e3f8-9f28-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Genital Herpes Infections</title>
                     <effectiveTime value="20230221"/>
                     <component>
                        <section>
                           <id root="3251e3f8-9f29-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Initial Episode</content>
                              </paragraph>
                              <paragraph>Six hundred forty-three immunocompetent adults with first-episode genital herpes who presented within 72 hours of symptom onset were randomized in a double-blind trial to receive 10 days of valacyclovir tablets 1 gram twice daily (n = 323) or oral acyclovir 200 mg 5 times a day (n = 320). For both treatment groups the median time to lesion healing was 9 days, the median time to cessation of pain was 5 days, and the median time to cessation of viral shedding was 3 days.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f2a-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Recurrent Episodes</content>
                              </paragraph>
                              <paragraph>Three double-blind trials (2 of them placebo-controlled) in immunocompetent adults with recurrent genital herpes were conducted. Subjects self-initiated therapy within 24 hours of the first sign or symptom of a recurrent genital herpes episode.</paragraph>
                              <paragraph>In 1 trial, subjects were randomized to receive 5 days of treatment with either valacyclovir tablets 500 mg twice daily (n = 360) or placebo (n = 259). The median time to lesion healing was 4 days in the group receiving valacyclovir tablets 500 mg versus 6 days in the placebo group, and the median time to cessation of viral shedding in subjects with at least 1 positive culture (42% of the overall trial population) was 2 days in the group receiving valacyclovir tablets 500 mg versus 4 days in the placebo group. The median time to cessation of pain was 3 days in the group receiving valacyclovir tablets 500 mg versus 4 days in the placebo group. Results supporting efficacy were replicated in a second trial.</paragraph>
                              <paragraph>In a third trial, subjects were randomized to receive valacyclovir tablets 500 mg twice daily for 5 days (n = 398) or valacyclovir tablets 500 mg twice daily for 3 days (and matching placebo twice daily for 2 additional days) (n = 402). The median time to lesion healing was about 4½ days in both treatment groups. The median time to cessation of pain was about 3 days in both treatment groups.</paragraph>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f2b-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Suppressive Therapy</content>
                              </paragraph>
                              <paragraph>Two clinical trials were conducted, one in immunocompetent adults and one in HIV-1-infected adults.</paragraph>
                              <paragraph>A double-blind, 12-month, placebo and active-controlled trial enrolled immunocompetent adults with a history of 6 or more recurrences per year. Outcomes for the overall trial population are shown in Table 8.</paragraph>
                              <table width="80%">
                                 <caption>Table 8. Recurrence Rates in Immunocompetent Adults at 6 and 12 Months</caption>
                                 <col width="15%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <col width="14%" align="center" valign="top"/>
                                 <thead>
                                    <tr styleCode="Botrule">
                                       <th styleCode="Lrule Rrule"/>
                                       <th colspan="3" styleCode="Rrule">6 Months</th>
                                       <th colspan="3" styleCode="Rrule">12 Months</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="middle">Outcome</th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  1 gram 
     <br/>  Once Daily 
     <br/>  (n = 269)
    </th>
                                       <th styleCode="Rrule">Oral Acyclovir 
     <br/>  400 mg 
     <br/>  Twice Daily 
     <br/>  (n = 267)
    </th>
                                       <th styleCode="Rrule" valign="middle">Placebo 
     <br/>  (n = 134)
    </th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 
     <br/>  1 gram 
     <br/>  Once Daily 
     <br/>  (n = 269)
    </th>
                                       <th styleCode="Rrule">Oral Acyclovir 
     <br/>  400 mg 
     <br/>  Twice Daily 
     <br/>  (n = 267)
    </th>
                                       <th styleCode="Rrule" valign="middle">Placebo 
     <br/>  (n = 134)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Recurrence free</td>
                                       <td styleCode="Rrule">55%</td>
                                       <td styleCode="Rrule">54%</td>
                                       <td styleCode="Rrule">7%</td>
                                       <td styleCode="Rrule">34%</td>
                                       <td styleCode="Rrule">34%</td>
                                       <td styleCode="Rrule">4%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Recurrences</td>
                                       <td styleCode="Rrule">35%</td>
                                       <td styleCode="Rrule">36%</td>
                                       <td styleCode="Rrule">83%</td>
                                       <td styleCode="Rrule">46%</td>
                                       <td styleCode="Rrule">46%</td>
                                       <td styleCode="Rrule">85%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Unknown
    
     <footnote ID="K4564">Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.</footnote>
                                       </td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">10%</td>
                                       <td styleCode="Rrule">19%</td>
                                       <td styleCode="Rrule">19%</td>
                                       <td styleCode="Rrule">10%</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Subjects with 9 or fewer recurrences per year showed comparable results with valacyclovir tablets 500 mg once daily.</paragraph>
                              <paragraph>In a second trial, 293 HIV-1-infected adults on stable antiretroviral therapy with a history of 4 or more recurrences of anogenital herpes per year were randomized to receive either valacyclovir tablets 500 mg twice daily (n = 194) or matching placebo (n = 99) for 6 months. The median duration of recurrent genital herpes in enrolled subjects was 8 years, and the median number of recurrences in the year prior to enrollment was 5.</paragraph>
                              <paragraph>Overall, the median pretrial HIV-1 RNA was 2.6 log
 
  <sub>10</sub>copies/mL. Among subjects who received valacyclovir tablets, the pretrial median CD4+ cell count was 336 cells/mm
 
  <sup>3</sup>; 11% had less than 100 cells/mm
 
  <sup>3</sup>, 16% had 100 to 199 cells/mm
 
  <sup>3</sup>, 42% had 200 to 499 cells/mm
 
  <sup>3</sup>, and 31% had greater than or equal to 500 cells/mm
 
  <sup>3</sup>.

 </paragraph>
                              <paragraph>Outcomes for the overall trial population are shown in Table 9.</paragraph>
                              <table width="60%">
                                 <caption>Table 9. Recurrence Rates in HIV-1-Infected Adults at 6 Months</caption>
                                 <col width="25%" align="left" valign="top"/>
                                 <col width="50%" align="center" valign="top"/>
                                 <col width="25%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="middle">Outcome</th>
                                       <th styleCode="Rrule">Valacyclovir Tablets 500 mg Twice Daily 
     <br/>  (n = 194)
    </th>
                                       <th styleCode="Rrule">Placebo 
     <br/>  (n = 99)
    </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Recurrence free</td>
                                       <td styleCode="Rrule">65%</td>
                                       <td styleCode="Rrule">26%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Recurrences</td>
                                       <td styleCode="Rrule">17%</td>
                                       <td styleCode="Rrule">57%</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Unknown
    
     <footnote ID="K4667">Includes lost to follow-up, discontinuations due to adverse events, and consent withdrawn.</footnote>
                                       </td>
                                       <td styleCode="Rrule">18%</td>
                                       <td styleCode="Rrule">17%</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="3251e3f8-9f2c-fa19-e063-6394a90a31d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Reduction of Transmission of Genital Herpes</content>
                              </paragraph>
                              <paragraph>A double-blind, placebo-controlled trial to assess transmission of genital herpes was conducted in 1,484 monogamous, heterosexual, immunocompetent adult couples. The couples were discordant for HSV-2 infection. The source partner had a history of 9 or fewer genital herpes episodes per year. Both partners were counseled on safer sex practices and were advised to use condoms throughout the trial period. Source partners were randomized to treatment with either valacyclovir tablets 500 mg once daily or placebo once daily for 8 months. The primary efficacy endpoint was symptomatic acquisition of HSV-2 in susceptible partners. Overall HSV-2 acquisition was defined as symptomatic HSV-2 acquisition and/or HSV-2 seroconversion in susceptible partners. The efficacy results are summarized in Table 10.</paragraph>
                              <table width="75%">
                                 <caption>Table 10. Percentage of Susceptible Partners Who Acquired HSV-2 Defined by the Primary and Selected Secondary Endpoints</caption>
                                 <col width="34%" align="left" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Endpoint</th>
                                       <th styleCode="Rrule">Valacyclovir Tablets
    
     <footnote ID="K4716">Results show reductions in risk of 75% (symptomatic HSV-2 acquisition), 50% (HSV-2 seroconversion), and 48% (overall HSV-2 acquisition) with valacyclovir tablets versus placebo. Individual results may vary based on consistency of safer sex practices.</footnote>(n = 743)
   
    </th>
                                       <th styleCode="Rrule">Placebo(n = 741)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Symptomatic HSV-2 acquisition</td>
                                       <td styleCode="Rrule">4 (0.5%)</td>
                                       <td styleCode="Rrule">16 (2.2%)</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">HSV-2 seroconversion</td>
                                       <td styleCode="Rrule">12 (1.6%)</td>
                                       <td styleCode="Rrule">24 (3.2%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Overall HSV-2 acquisition</td>
                                       <td styleCode="Rrule">14 (1.9%)</td>
                                       <td styleCode="Rrule">27 (3.6%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20230221"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.3">
                     <id root="3251e3f8-9f2d-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3 Herpes Zoster</title>
                     <text>
                        <paragraph>Two randomized double-blind clinical trials in immunocompetent adults with localized herpes zoster were conducted. Valacyclovir tablets was compared with placebo in subjects aged less than 50 years, and with oral acyclovir in subjects aged greater than 50 years. All subjects were treated within 72 hours of appearance of zoster rash. In subjects aged less than 50 years, the median time to cessation of new lesion formation was 2 days for those treated with valacyclovir tablets compared with 3 days for those treated with placebo. In subjects aged greater than 50 years, the median time to cessation of new lesions was 3 days in subjects treated with either valacyclovir tablets or oral acyclovir. In subjects aged less than 50 years, no difference was found with respect to the duration of pain after healing (post-herpetic neuralgia) between the recipients of valacyclovir tablets and placebo. In subjects aged greater than 50 years, among the 83% who reported pain after healing (post-herpetic neuralgia), the median duration of pain after healing (95% CI) in days was: 40 [31, 51], 43 [36, 55], and 59 [41, 77] for 7-day valacyclovir tablets, 14-day valacyclovir tablets, and 7-day oral acyclovir, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section ID="S14.4">
                     <id root="3251e3f8-9f2e-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.4 Chickenpox</title>
                     <text>
                        <paragraph>The use of valacyclovir tablets for treatment of chickenpox in pediatric subjects aged 2 to less than 18 years is based on single-dose pharmacokinetic and multiple-dose safety data from an open-label trial with valacyclovir and supported by safety and extrapolated efficacy data from 3 randomized, double-blind, placebo-controlled trials evaluating oral acyclovir in pediatric subjects.</paragraph>
                        <paragraph>The single-dose pharmacokinetic and multiple-dose safety trial enrolled 27 pediatric subjects aged 1 to less than 12 years with clinically suspected VZV infection. Each subject was dosed with valacyclovir oral suspension, 20 mg/kg 3 times daily for 5 days. Acyclovir systemic exposures in pediatric subjects following valacyclovir oral suspension were compared with historical acyclovir systemic exposures in immunocompetent adults receiving the solid oral dosage form of valacyclovir or acyclovir for the treatment of herpes zoster. The mean projected daily acyclovir exposures in pediatric subjects across all age-groups (1 to less than 12 years) were lower (C
 
  <sub>max</sub>: ↓13%, AUC: ↓30%)than the mean daily historical exposures in adults receiving valacyclovir 1 gram 3 times daily, but were higher (daily AUC: ↑50%) than the mean daily historical exposures in adults receiving acyclovir 800 mg 5 times daily. The projected daily exposures in pediatric subjects were greater (daily AUC approximately 100% greater) than the exposures seen in immunocompetent pediatric subjects receiving acyclovir 20 mg/kg 4 times daily for the treatment of chickenpox. Based on the pharmacokinetic and safety data from this trial and the safety and extrapolated efficacy data from the acyclovir trials, oral valacyclovir 20 mg/kg 3 times a day for 5 days (not to exceed 1 gram 3 times daily) is recommended for the treatment of chickenpox in pediatric patients aged 2 to less than 18 years. Because the efficacy and safety of acyclovir for the treatment of chickenpox in children aged less than 2 years have not been established, efficacy data cannot be extrapolated to support valacyclovir treatment in children aged less than 2 years with chickenpox.

 </paragraph>
                        <paragraph>Valacyclovir is also not recommended for the treatment of herpes zoster in children because safety data up to 7 days' duration are not available
 
  <content styleCode="italics">[see
  
   <linkHtml href="#S8.4">Use in Specific Populations (8.4)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="3251e3f8-9f2f-fa19-e063-6394a90a31d1"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Valacyclovir Tablets, USP 500 mg (blue, film-coated, capsule-shaped tablets debossed with "Y131" on one side) containing 556.2 mg of valacyclovir hydrochloride equivalent to 500 mg valacyclovir.</paragraph>
                  <table width="40%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottle of 30 (NDC 69367-262-30).</td>
                        </tr>
                        <tr>
                           <td>Bottle of 90 (NDC 69367-262-09).</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Valacyclovir Tablets, USP 1 gram (blue, film-coated, capsule-shaped tablets, with a partial scorebar on both sides, debossed with "Y132" on one side) containing 1.112 grams of valacyclovir hydrochloride equivalent to 1 gram valacyclovir.</paragraph>
                  <table width="40%" styleCode="Noautorules">
                     <col width="100%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>Bottle of 30 (NDC 69367-263-30).</td>
                        </tr>
                        <tr>
                           <td>Bottle of 90 (NDC 69367-263-09).</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20230221"/>
               <component>
                  <section>
                     <id root="3251e3f8-9f30-fa19-e063-6394a90a31d1"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage:</content>
                        </paragraph>
                        <paragraph>Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="3251e3f8-9f31-fa19-e063-6394a90a31d1"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-Approved Patient Labeling (Medication Guide，available at www.wprx- .com/prescription-catalog).</paragraph>
               </text>
               <effectiveTime value="20230221"/>
               <component>
                  <section>
                     <id root="3251e3f8-9f32-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Importance of Adequate Hydration</content>
                        </paragraph>
                        <paragraph>Patients should be advised to maintain adequate hydration.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3251e3f8-9f33-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Missed Dose</content>
                        </paragraph>
                        <paragraph>Instruct patients that if they miss a dose of valacyclovir tablets, to take it as soon as they remember. Advise patients not to double their next dose or take more than the prescribed dose.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3251e3f8-9f34-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Cold Sores (Herpes Labialis)</content>
                        </paragraph>
                        <paragraph>Patients should be advised to initiate treatment at the earliest symptom of a cold sore (e.g., tingling, itching, or burning). There are no data on the effectiveness of treatment initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer). Patients should be instructed that treatment for cold sores should not exceed 1 day (2 doses) and that their doses should be taken about 12 hours apart. Patients should be informed that valacyclovir tablets is not a cure for cold sores.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3251e3f8-9f35-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Genital Herpes</content>
                        </paragraph>
                        <paragraph>Patients should be informed that valacyclovir tablets is not a cure for genital herpes. Because genital herpes is a sexually transmitted disease, patients should avoid contact with lesions or intercourse when lesions and/or symptoms are present to avoid infecting partners. Genital herpes is frequently transmitted in the absence of symptoms through asymptomatic viral shedding. Therefore, patients should be counseled to use safer sex practices in combination with suppressive therapy with valacyclovir tablets. Sex partners of infected persons should be advised that they might be infected even if they have no symptoms. Type-specific serologic testing of asymptomatic partners of persons with genital herpes can determine whether risk for HSV-2 acquisition exists.</paragraph>
                        <paragraph>Valacyclovir tablets has not been shown to reduce transmission of sexually transmitted infections other than HSV-2.</paragraph>
                        <paragraph>If medical management of a genital herpes recurrence is indicated, patients should be advised to initiate therapy at the first sign or symptom of an episode.</paragraph>
                        <paragraph>There are no data on the effectiveness of treatment initiated more than 72 hours after the onset of signs and symptoms of a first episode of genital herpes or more than 24 hours after the onset of signs and symptoms of a recurrent episode.</paragraph>
                        <paragraph>There are no data on the safety or effectiveness of chronic suppressive therapy of more than 1 year's duration in otherwise healthy patients. There are no data on the safety or effectiveness of chronic suppressive therapy of more than 6 months' duration in HIV-1-infected patients.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3251e3f8-9f36-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Herpes Zoster</content>
                        </paragraph>
                        <paragraph>There are no data on treatment initiated more than 72 hours after onset of the zoster rash. Patients should be advised to initiate treatment as soon as possible after a diagnosis of herpes zoster.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3251e3f8-9f37-fa19-e063-6394a90a31d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Chickenpox</content>
                        </paragraph>
                        <paragraph>Patients should be advised to initiate treatment at the earliest sign or symptom of chickenpox.</paragraph>
                     </text>
                     <effectiveTime value="20230221"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3251e3f8-9f38-fa19-e063-6394a90a31d1"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured by: 
  <br/>  Yiling Pharmaceutical Ltd 
  <br/>  No.36 Zhujiang Road, Shijiazhuang, 050035, China
 </paragraph>
                  <paragraph>Distributed by: 
  <br/>  Westminster Pharmaceuticals, LLC 
  <br/>  1321 Murfreesboro Pike, Ste 607, Nashville, TN 37217, USA
 </paragraph>
                  <paragraph>Revised: 02/2023</paragraph>
               </text>
               <effectiveTime value="20230221"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3251e3f8-9f39-fa19-e063-6394a90a31d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 69367-262-09</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Valacyclovir 
  <br/>  Tablets, USP 
  <br/>  500 mg
 </paragraph>
                  <paragraph>Dispense the Medication Guide provided 
  <br/>  separately to each patient.
 </paragraph>
                  <paragraph>90 Tablets</paragraph>
                  <paragraph>Westminster 
  <br/>  Pharmaceuticals
 </paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20230221"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>PRINCIPAL DISPLAY PANEL - 500 mg Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="valacyclovir-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3251e3f8-9f3a-fa19-e063-6394a90a31d1"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1 gram Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 69367-263-09</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Valacyclovir 
  <br/>  Tablets, USP 
  <br/>  1 gram
 </paragraph>
                  <paragraph>Dispense the Medication Guide provided 
  <br/>  separately to each patient.
 </paragraph>
                  <paragraph>90 Tablets</paragraph>
                  <paragraph>Westminster 
  <br/>  Pharmaceuticals
 </paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20230221"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - 1 gram Tablet Bottle Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="valacyclovir-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>